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ABSTRACT Cerebral cholinergic deficits have been described in Alzheimer disease
(AD) and as a result of normal aging. At the present time, there are very limited options
for the quantification of cholinergic receptors with in vivo imaging techniques such as
PET. In the present study, we examined the feasibility of utilizing [11C]N-methyl-4-
piperidyl benzilate (NMPB), a nonselective muscarinic receptor ligand, in the study of
aging and neurodegenerative processes associated with cholinergic dysfunction. Based
on prior data describing the accuracy of various kinetic methods, we examined the
concentration of muscarinic receptors with [11C]NMPB and PET using two- and three-
compartment kinetic models. Eighteen healthy subjects and six patients diagnosed with
probable AD were studied. Pixel-by-pixel two-compartment model fits showed acceptable
precision in the study of normal aging, with comparable results to those obtained with
a more complex and less precise three-compartment model. Normal aging was associ-
ated with a reduction in muscarinic receptor binding in neocortical regions and thala-
mus. In AD patients, the three-compartment model appeared capable of dissociating
changes in tracer transport from changes in receptor binding, but suffered from statis-
tical uncertainty, requiring normalization to a reference region, and therefore limiting
its potential use in the study of neurodegenerative processes. After normalization, no
regional changes in muscarinic receptor concentrations were observed in AD. Synapse
39:275–287, 2001. © 2001 Wiley-Liss, Inc.
INTRODUCTION
Cholinergic deficits, with marked reductions in the
enzymes choline acetyltransferase and acetylcholines-
terase, and cholinergic neuronal loss have been re-
ported even at early stages of Alzheimer disease (AD),
both in biopsied tissue and in postmortem studies (Da-
vies and Maloney, 1976; White et al., 1977; Perry et al.,
1978; Bowen et al., 1982; Sims et al., 1983; DeKosky et
al., 1992). Reductions in cholinergic function may then
be responsible for some of the deficits encountered in
this illness. Specifically, both neuronal loss and choline
acetyltransferase activity have been correlated with
measures of cognitive function in AD patients (Perry et
al., 1978; Wilcock et al., 1982; DeKosky and Scheff,
1990; Terry et al., 1991; DeKosky et al., 1992).
Some controversy exists regarding the status of cho-
linergic receptors in AD. In vitro autopsy and biopsy
findings point towards unaltered total muscarinic re-
ceptor densities in AD, compared with control autop-
sies (Davies and Verth, 1978; Perry et al., 1978;
Sakurada et al., 1990; Schroder et al., 1991; DeKosky
et al., 1992). Conversely, brain imaging studies per-
formed with [123I]quinuclidinyl benzilate (QNB) and
SPECT in living subjects diagnosed with probable AD
have described focal reductions in [123I]QNB distribu-
tion in neocortical regions (Holman et al., 1985; Wein-
berger et al., 1991, 1992; Wyper et al., 1993). In one of
these studies, focal reductions in [123I]QNB binding
were more extensive than those encountered with
[18F]2-fluoro-2-deoxyglucose (FDG), and it was pro-
posed that the cholinergic marker would be a more
sensitive measure of the extent of AD than the meta-
bolic maps (Weinberger et al., 1992). Data recently
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presented by another group, using [11C]N-methyl-4-
piperidyl benzylate (NMPB) and PET, with a graphical
analysis approach, using cerebellum as input function,
also showed reductions in tracer distribution in the
parietal cortex of patients diagnosed with probable AD
(Ichimiya et al., 1995).
A similar situation has been encountered in studies
exploring cholinergic changes associated with normal
aging. An increased sensitivity to the effects of musca-
rinic antagonists have been described with advancing
age in humans (Molchan et al., 1992), suggesting age-
related alterations in the number or function of cholin-
ergic receptors. In vitro binding studies have found
moderately decreased or unchanged total populations
of muscarinic cholinergic receptors during normal ag-
ing in human postmortem samples (Giacobini, 1990;
Schroder et al., 1991; Nordberg et al., 1992). In exper-
imental animals, regionally selective alterations have
been reported, with some studies describing moderate
reductions in muscarinic receptor number in neocorti-
cal regions, basal ganglia, thalamic, and pontine nuclei
(Biegon et al., 1988), and others finding no significant
change with age (Pearce et al., 1992; Wang et al., 1992).
Larger declines in radioligand binding have been de-
scribed using brain imaging techniques. In a PET
study with [N-11C-methyl]-benztropine, Dewey et al.
(1990) reported reductions in specific radioligand bind-
ing as a function of age in neocortical and basal ganglia
regions, but unchanged distribution in thalamus, hip-
pocampus, or cerebellum. Using [11C]NMPB and a
graphical analysis method with cerebellum as input
function, Suhara et al. (1993) described very large de-
creases in radioligand distribution in all brain regions
studied, which included neocortical, basal ganglia, and
other subcortical structures. A subsequent publication,
in which young and elderly subjects were studied with
the nonselective muscarinic receptor antagonist [11C]-
tropanyl benzylate (TRB) and PET, showed relatively
minor reductions in frontal cortical binding, and in-
creases in the cerebellum and midbrain (Lee et al.,
1996).
While it is possible that some differences between
autopsy and receptor imaging studies with PET or
SPECT may exist because of postmortem changes
(Brady and Mufson, 1990), methodological issues asso-
ciated with muscarinic receptor quantification with
PET or SPECT are likely to be responsible for some of
these discrepancies. The success of SPECT and PET
tomographic analysis to obtain accurate binding infor-
mation for the muscarinic system has been hampered
by the in vivo kinetic behavior of the different radio-
tracers employed, which have included [11C]scopol-
amine (Frey et al., 1992), [11C]tropanyl benzilate (Ko-
eppe et al., 1994), [11C]benztropine (Dewey et al.,
1990a,b), [123I]-3-quinuclidinyl-4-iodobenzilate (Eckel-
man et al., 1984; Sawada et al., 1990), and [123I]iodo-
dexetimide (Müeller-Gärtner et al., 1992). Typically,
these agents display long equilibration times due to
slow ligand-receptor dissociation and/or overly rapid
binding relative to the rate of ligand transport across
the blood–brain barrier back out of the brain. Accurate
quantification of regional receptor densities becomes
difficult under these circumstances. Slow dissociation
of the ligand from receptor sites precludes using equi-
librium modeling or single scan analysis, since true
equilibration is not achieved during the scanning pe-
riod. When the rate of binding is too rapid (relative to
the rate of transport), this results in a delivery-limited
condition in which the receptor measures become sen-
sitive to changes in blood flow (Koeppe, 1990; Koeppe et
al., 1994). Additionally, biases are introduced into the
measurements when it is assumed that cerebellar con-
centrations of tracer are equivalent to free tracer con-
centration in other brain regions (Ichimiya et al., 1995,
Suhara et al., 1993, 1994). This is due to a significant
degree of specific binding in the cerebellum, and free
tracer concentrations that may vary regionally (Zu-
bieta et al., 1998). Furthermore, as binding density
increases the concentration of free ligand decreases
and, thus, even with equivalent free 1 nonspecific dis-
tribution volumes, the level of free tracer in basal gan-
glia will be considerably lower than in cerebellum.
We have developed a radiolabeled muscarinic recep-
tor antagonist, [11C]NMPB (Mulholland et al., 1988),
which in human studies with PET (Zubieta et al., 1998)
appears to present more favorable kinetic properties
than prior compounds (Koeppe et al., 1992). In these
initial studies, various quantification models were
evaluated for their ability to provide unbiased esti-
mates of receptor density. On the basis of those obser-
vations, only models utilizing arterial blood sampling
and kinetic modeling were able to accurately dissociate
changes in tracer transport from receptor binding. A
simplified, pixel-by-pixel implementation of a weight-
ed-integral two-compartment model was deemed ade-
quate for the estimation of receptor binding when
tracer transport was not severely altered. When tracer
delivery was modified by relatively large changes in
regional cerebral blood flow (rCBF), a more complex
three-compartment model was necessary to isolate
changes in tracer transport from receptor binding mea-
sures (Zubieta et al., 1998).
In the present report, both approaches were utilized
for the quantification of muscarinic receptor binding
with [11C]NMPB and PET. In the case of subjects di-
agnosed with probable AD, large reductions in cerebral
blood flow and metabolism have been reported in brain
regions most affected by the disease (Frackowiak et al.,
1981; Benson et al., 1983; Haxby et al., 1990; Bonte et
al., 1993). Under these conditions, the simplified model
would not be likely to completely isolate changes in
ligand transport from changes in actual receptor bind-
ing. To reduce the possibility that perceived changes in
radioligand distribution were being induced by alter-
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ations in its delivery, both a pixel-by-pixel two-com-
partment and three-compartment tracer kinetic mod-




Eighteen healthy volunteers of ages ranging from
21–83 years old (mean 6 1 SD, 40 6 23), 11 males,
seven females, were recruited via local newspaper ad-
vertisements and studied after undergoing physical
and neurological examinations. The subjects had no
significant medical, neurological, or psychiatric his-
tory, or family history of neurological or psychiatric
illness in first-degree relatives. They were also
screened for drug or alcohol use, smoking, or excessive
consumption of caffeine. A subgroup of six older age-
and gender-matched (69 6 10 years old) healthy vol-
unteers were selected for comparison with patients
diagnosed with AD. The studies were approved by the
University of Michigan Institutional Review Boards
governing the use of human subjects and the use of
radionuclides in human research, and written in-
formed consent was obtained prior to all experimental
procedures.
A group of six subjects diagnosed with probable AD
(65 6 10 years old, four females, two males) were
recruited from a pool of patients included in a longitu-
dinal follow-up study at the Alzheimer’s Disease Re-
search Center at the University of Michigan. They met
ADRDA/NINCDS (McKhann et al., 1984) and DSM-
III-R criteria (APA, 1987) for probable Alzheimer’s dis-
ease. All six subjects underwent neuropsychological
testing and neurological examinations prior to scan-
ning, which supported the clinical diagnosis. At the
time of PET scanning, Mini-Mental Status scores were
17 6 3 (range 11–22), Hachinski Ischemic Scale scores
were 1 6 1 (range 0–2), and Hamilton Depression
Rating Scale scores were below 4 in all cases. Addition-
ally, all patients displayed a typical biparietal hypo-
metabolic pattern of AD in [18F]FDG PET scans, which
were performed prior to scheduling receptor imaging
with [11C]NMPB.
Scanning procedures
Radial artery and antecubital vein catheters were
placed for collection of arterial blood samples and for
radiotracer administration, respectively. The subjects
were then positioned supine in the gantry of a CTI/
Siemens 931/08-12 scanner. This tomograph acquires
15 contiguous slices, covering a ;10 cm field of view
with a reconstructed in-plane resolution of ;7–8 mm
at FWHM. Subject positioning was standardized using
laser beams, with the canto-meatal line selected as
imaging plane. Each scan was initiated after the intra-
venous bolus administration of no-carrier-added, high
specific activity (.1,000 Ci/mmol) [11C]NMPB (Mulhol-
land et al., 1988). Two different dosing protocols were
utilized. Young healthy controls received 20 6 2 mCi
[11C]NMPB. Elderly healthy controls (n 5 6) and pa-
tients diagnosed with AD received 39 6 3 mCi, after
[11C]NMPB dosimetry was reevaluated. All subjects
were scanned with eyes and ears unoccluded in a room
with dimmed light and background white noise.
A sequence of 18 PET scans were acquired covering
110 min (2 3 30 sec, 4 3 1 min, 2 3 2.5 min, 2 3 5 min,
7 3 10 min, 1 3 20 min). Blood samples were with-
drawn from the radial artery, as rapidly as possible for
the first 2 min of the scanning period, and then at 2.5,
3, 4, 5, 7.5, 10, 15, 20, 30, 45, 60, 85, and 110 min
postinjection.
Patients diagnosed with AD also underwent
[18F]FDG scans approximately 1 week prior to the re-
ceptor studies to support the clinical diagnosis. Ten
mCi of [18F]FDG were injected intravenously. Begin-
ning 30 min postinjection, two sets of interleaved static
images were obtained. The FDG activity maps were
subsequently reoriented to match the parametric K1
maps obtained from the NMPB scans by using an im-
age coregistration computer algorithm (Minoshima et
al., 1992).
Metabolite correction of the arterial
input function
A total of 14 plasma samples were analyzed for the
presence of metabolites. A rapid Sep-Pak C18 car-
tridge, reverse-phase chromatographic technique was
utilized (Zubieta et al., 1998). The arterial blood was
centrifuged and the plasma applied to the column. A
metabolite fraction was obtained by washing the col-
umn with 9 ml of a 36% ethanol/sodium borate buffer
(pH 10) solution. The NMPB fraction was then eluted
with 5 ml 100% ethanol. The separation was corrected
for the loss of NMPB in the metabolite fraction by the
use of [3H]NMPB added to the plasma sample prior to
processing. The [11C]NMPB and [11C]metabolite frac-
tions were determined in the well counter, and the
recovery of [3H]NMPB from the cartridges was quan-
tified by liquid scintillation spectrometry.
Motion correction and image realignment
Given the duration of the scanning period, the recon-
structed NMPB images were realigned to correct for
patient motion that may have occurred during the
study. Molecular sieve beads (1–2 mm in diameter)
were placed at various points on the subject’s scalp
prior to the study. Six to eight mCi of [11C]NMPB in a
volume of ;1 ml were used to label the beads. Following
reconstruction of the dynamic PET scan sequence, each
bead was marked with a cursor in the 17th frame of the
study and used as base orientation. The (x,y,z) coordi-
nates were then calculated based on the radioactivity
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distribution in the vicinity of the beads. An automated
routine located and calculated the (x,y,z) coordinates
for each bead in the remaining 17 frames, which were
then realigned to the orientation of the base frame.
This method corrects for the three translational and
three rotational degrees of freedom, and realigns image
sets to within 0.5 mm and 1°, respectively.
Tracer kinetic analysis of [11C]NMPB
transport and distribution
The tracer kinetic analysis technique utilized for
[11C]NMPB is similar to that described in detail in
prior studies from our group (Frey et al., 1985, 1992;
Koeppe et al., 1992, 1994; Zubieta et al., 1998). The
model includes a plasma compartment (CP) and a tis-
sue compartment with three subcompartments. These
represent free (CF), nonspecifically bound (CNS), and
specifically bound (CS) radiotracer, with its exchange
being governed by six rate constants (K1-k6). Practi-
cally, this model is too complex for implementation
with PET studies when only one tracer dose is admin-
istered. Two simplified configurations were utilized for
the present analysis. A three-compartment, four-pa-
rameter model was applied, which included transport
(K1), the free plus nonspecific distribution volume
(DV9), and the receptor binding and dissociation rate
constants (k93 and k4). This configuration combines the
free and nonspecific pools into a single compartment
(CF1NS) and assumes that the rate constants of ex-
change with the nonspecific pool (k5 and k6) are rapid
compared to blood–brain barrier and receptor binding
transport rates (K1-k4). The kinetic parameters are
defined in the four-compartment model as follows:
K1 5 fE0 5 f~1 2 e 2 PS/f! ~ml g21 min21!





In the simplified three-compartment model, these rate
constants are modified to:
k92 5 k2/~1 1 k5/k6! 5 K1/DV9 ~min21!
5 K1/DVF~1 1 k5/k6! 5 K1/~DVF 1 NS!
k93 5 k3f2 ~min21!
5 k3/~1 1 k5/k6!
5 konB9max/~1 1 k5/k6!
where ƒ is cerebral blood flow (ml g-1 min-1), E0 is the
single pass extraction fraction of the ligand across the
blood–brain barrier, PS is the capillary permeability
surface area product (ml g-1 min-1), kon is the bimolec-
ular association rate between ligand and receptor (g
pmol-1 min-1), B9max is the density of available receptors
(pmol g-1), koff is the dissociation rate of ligand from the
receptor complex (min-1), Kd the equilibrium ligand
binding constant for the receptor site, and DV9 is the
summed distribution volume of the combined free and
nonspecifically bound compartments (ml g-1). The
quantity (1 1 k5/k6) reflects then the increase in size of
the receptor binding precursor compartment due to
nonspecific binding. Assuming that the free tracer com-
partment achieves rapid equilibrium and (K1/k2) ap-
proximates 1, the value of k3 can be calculated from k93;
k3 5 k93 [(K1/k2)/(1 1 k5/k6)] 5 k93DV9, ' k3f2. The ratio
of receptor-related parameters k3/k4 5 B9max/Kd is then
proportional to receptor binding, provided that Kd re-
mains constant between regions, and has been referred
to as the “binding potential” by Mintun et al. (1984).
Parameters were estimated by standard nonlinear
least-squares analysis using the Marquardt algorithm
(Bevington, 1969) with constraints restricting param-
eters to positive values. The effects of a cerebral blood
volume (CBV) component in the measured PET data
(tissue response) and the time offset between the
plasma input function obtained from the radial artery
and the brain activity time course were accounted for
in the models. The time offset was calculated by fitting
the time–activity curve of an entire slice at the mid-
thalamic level to a two-compartment, two-parameter
model, using only the first 20 min of data. In this fit, a
whole-slice CBV of 0.035 ml g-1 (3.5%) was assumed. In
all subsequent fits, the time offset was fixed to the
estimated value. Local values of CBV were estimated
in the individual regions as an additional model pa-
rameter.
A two-parameter, pixel-by-pixel weighted integral
analysis (Alpert et al., 1984) was also utilized. If, in
addition to rapid equilibration of free and nonspecific
compartments, the binding and release of the ligand
are rapid compared to the transport parameters K1 and
k92, the model can be reduced to two compartments. In
this simplified model, a single tissue compartment in-
corporates free, nonspecifically bound, and specifically
bound tracer with a new k02 rate constant reflecting the
net back transport of tracer into the plasma compart-
ment, which is defined as:
k 02 5 k2/~1 1 k5/k6 1 k3/k4! ~min21!
5 K1/~DVF 1 DVNS 1 DVS! 5 K1/DV0
and thus
DV0 5 K1/k2~1 1 k5/k6 1 k3/k4!
5 DVF 1 NS 1 DVFB9max/Kd
where DV0 is the apparent distribution volume of the
summed tissue compartments (K1/k02). In this model,
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receptor information is represented only by DV0. As the
ratio of association to dissociation rate (k3/k4) becomes
progressively higher, the specific distribution volume
term dominates, and DV0 yields a progressively better
estimate of B9max/Kd. This approach yields parametric
images of ligand delivery (K1) and receptor binding
(DV0). In this case, the first 30 sec of scan data were
omitted from the calculations to reduce CBV effects on
the estimated parameters (Koeppe et al., 1987).
Data analysis
For examination of the effects of aging on the re-
gional patterns of [11C]NMPB transport and receptor
binding, irregular regions of interest (ROIs) were
drawn on the K1 images obtained from the weighted
integral pixel-by-pixel analysis, following the contour
of the gray matter. These ROIs were then applied to
the DV0 images of that subject. In the case of the AD
patients, homologous ROIs were identified in the met-
abolic images obtained with [18F]FDG, and were then
applied to K1 and DV0 pixel-by-pixel maps. This al-
lowed for a more accurate delimitation of the cortical
regions (parietal cortex) that showed abnormal meta-
bolic patterns in the FDG images.
Statistical comparisons between controls and AD pa-
tients or between groups within the healthy subjects
were performed via ANOVA for multiple comparisons
(regions). When the ANOVA detected a significant in-
teraction, regional differences between groups were
then evaluated with post-hoc Dunnett’s t-tests, with a
minimum level of significance of P , 0.05. Associations
between age and radioligand transport or ligand bind-
ing values were tested with nonparametric Spearman’s
rank correlations, with a minimum level of significance
of P , 0.05. Values are expressed as the mean 6 1 SD.
RESULTS
Age-dependency of [11C]NMPB transport
and binding parameters
The association between regional and whole brain K1
and binding potential values with age is shown in
Table I. No significant correlations were observed be-
tween tracer transport and age for any of the brain
regions considered. Conversely, binding estimates ob-
tained with either a pixel-by-pixel or a three-compart-
ment model showed significant reductions with ad-
vancing age in neocortical regions (frontal and occipital
cortex) and thalamus (Table I, Fig. 1). Whole brain
values obtained with the pixel-by-pixel two-compart-
ment model were also significantly decreased with age.
Pons reached statistically significant correlations only
in the simpler model configuration, but not in the three-
compartment model. No significant correlations with age
were obtained for putamen and cerebellum with either of
the two models (Spearman’s rank correlation, P . 0.05).
When the binding values obtained in the youngest
cohort studied (second decade of age, 23 6 2, n 5 10)
were compared with those in older subjects (age . 55,
mean 69 6 11 years old, n 5 6), ANOVA with repeated
measures identified an age-group by region interaction
(P , 0.01) for both DV0 (two-compartment model) and
k3/k4 (three-compartment) values. For DV0 post-hoc
Dunnett’s t-tests showed significant reductions (P ,
0.05) in frontal cortex (mean change 26%), occipital
cortex (mean change 30%), thalamus (26%), and whole
brain (23%), but no significant differences in putamen
(12%), pons (22%), and cerebellum (no changes noted).
Similarly to the above results, when the k3/k4 values
obtained with the three-compartment model were com-
pared between the younger and older cohorts, signifi-
cant differences were obtained in frontal cortex, occipital
cortex, and thalamus, with mean reductions in binding
values of 35%, 34%, and 32%, respectively. Again, no
significant differences were reached in putamen (mean





In Table II we show the regional distribution of
tracer transport (K1) and receptor binding (DV0) val-
TABLE I. Spearman’s rank correlations between age and regional [11C]NMPB transport rates (K1 )




K1 (P value) DV0 (P value) K1 (P value) k3/k4 (P value)
Frontal cortex 20.42 (0.09) 20.55 (0.02)* 20.16 (0.5) 20.62 (0.01)*
Occipital cortex 20.03 (0.9) 20.51 (0.04)* 20.42 (0.09) 20.54 (0.03)*
Putamen 20.28 (0.2) 20.37 (0.13) 0.16 (0.5) 20.37 (0.2)
Thalamus 20.19 (0.2) 20.53 (0.03)* 20.13 (0.6) 20.58 (0.02)*
Pons 0.21 (0.4) 20.54 (0.03)* 0.20 (0.4) 20.26 (0.3)
Cerebellum 0.11 (0.6) 20.13 (0.6) 0.16 (0.5) 0.11 (0.7)
Whole brain 20.41 (0.08) 20.55 (0.02)* — —
Spearman’s rank correlation coefficients and significance levels (in parentheses) between age and [11C]NMPB transport
and binding parameters in 18 healthy subjects. In the first two columns the values express the correlation coefficients for
the transport rate (K1) and binding parameter (DV0) obtained from a two-compartment model with a pixel-by-pixel
implementation. The last two columns show the values corresponding to regional three-compartment fits, in which the
binding parameter is defined as the ratio k3/k4.
*Statistically significant at a level of P , 0.05.
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Fig. 1. Correlations between age and re-
gional receptor density estimations obtained
with a pixel-by-pixel implementation of a
two-compartment model and a three-com-
partment model. Data presented correspond
to three representative regions, two of which
showed negative correlations with age and
one (cerebellum) in which no association be-
tween age and receptor concentrations were
noted.
TABLE II. [11C]NMPB kinetic parameter estimates, two-compartment weighted integral pixel-by-pixel fits;
Alzheimer disease, age-matched elderly controls, and young controls
Regions
K1 DV0
AD ECtr YCtr AD ECtr YCtr
Frontal cortex 0.24 (0.04)* 0.32 (0.03) 0.31 (0.05) 32 (11) 39 (13) 42 (9)
Parietal cortex 0.20 (0.06)* 0.31 (0.03) 0.29 (0.05) 21 (6)* 38 (13) 40 (10)
Occipital cortex 0.32 (0.08)* 0.36 (0.02) 0.33 (0.06) 34 (5) 39 (13) 46 (11)
Putamen 0.30 (0.04) 0.39 (0.05) 0.35 (0.04) 37 (11) 53 (17) 48 (13)
Thalamus 0.28 (0.04)* 0.36 (0.02) 0.32 (0.05) 22 (6) 29 (9) 32 (9)
Pons 0.24 (0.02)* 0.33 (0.07) 0.25 (0.04) 17 (3) 20 (6) 22 (7)
Cerebellum 0.28 (0.02) 0.35 (0.09) 0.30 (0.04) 7 (2) 8 (2) 7 (3)
Whole brain 0.19 (0.03)* 0.26 (0.02) 0.25 (0.04) 23 (6) 29 (9) 32 (7)
Region/Thalamus Ratios
Frontal cortex 0.85 (0.15) 0.89 (0.09) 0.99 (0.08) 1.42 (0.21) 1.37 (0.15) 1.32 (0.12)
Parietal cortex 0.71 (0.17)* 0.85 (0.08) 0.91 (0.05) 0.99 (0.14)* 1.32 (0.16) 1.23 (0.13)
Occipital cortex 1.16 (0.22) 1.00 (0.05) 1.05 (0.07) 1.63 (0.30) 1.38 (0.19) 1.43 (0.12)
Putamen 1.07 (0.15) 1.06 (0.12) 1.12 (0.11) 1.70 (0.22) 1.87 (0.16)** 1.49 (0.23)
Pons 0.86 (0.12) 0.90 (0.19) 0.80 (0.09) 0.77 (0.10) 0.72 (0.13) 0.67 (0.12)
Cerebellum 1.01 (0.19) 0.96 (0.24) 0.96 (0.15) 0.31 (0.03) 0.29 (0.07)** 0.20 (0.04)
Whole brain 0.67 (0.07) 0.70 (0.06) 0.78 (0.02) 1.03 (0.08) 1.04 (0.10) 1.01 (0.09)
Transport rate constants (K1) and distribution volume (DV0) of [
11C]NMPB in patients diagnosed with Alzheimer disease (AD), age-matched elderly controls (ECtr),
and a young control reference group (YCtr), calculated from a two-compartment model, implemented in a pixel-by-pixel basis (standard deviation of the mean in
parentheses). Statistical comparisons were performed between AD and ECtr, and between ECtr and YCtr groups.
*Significantly different from elderly age-matched controls, ANOVA with post-hoc Dunnett t-tests, P , 0.05.
**Comparison between elderly controls and young controls, significant at level P , 0.05 (ANOVA with Dunnett t-test).
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ues, using a pixel-by-pixel, two-parameter, two-com-
partment model analysis, in six subjects diagnosed
with AD. As a comparison group, we show results for
six age-matched elderly controls. An additional refer-
ence group consisting of six young healthy subjects
(27 6 5 years old) was also included in the table to
facilitate comparisons across age groups. Statistical
comparisons were performed between AD and age-
matched elderly controls, and between elderly and
young control groups.
Regional and whole brain K1 values were generally
lower in the patient group, compared with age-matched
controls, with the exception of putamen and cerebel-
lum, which did not show significant differences. Mean
reductions in K1 ranged from 35% (parietal cortex) to
20% (putamen, cerebellum).
Regional K1 values were also normalized to those of
the thalamus, selected as an area that does not show
clear changes in cerebral blood flow or metabolism in
AD (see Discussion). After normalization, the ratios
ROI/thalamus were not different between AD patients
and elderly controls, or between elderly controls and
young controls. The only exception was the parietal
cortex, in which statistically significant reductions in
K1 rates in AD were still apparent. Ratio values in the
occipital cortex were slightly higher in AD than in the
control groups; although the differences did not reach
statistical significance, they probably reflect relatively
preserved rCBF and tracer transport in this region. No
significant differences in K1 were observed between
elderly and young controls groups for absolute or nor-
malized values (ANOVA P . 0.05).
The receptor-related parameter DV0 was also gener-
ally lower in AD subjects than in age-matched controls
for most regions and whole brain, although the only
area in which these differences reached statistical sig-
nificance was the parietal cortex (mean difference
43%). Other regions showed mean reductions of 19%
(frontal cortex), 12% (occipital cortex), 30% (putamen),
24% (thalamus), 18% (pons), and 16% (cerebellum).
After normalization to thalamic DV0 values, the mod-
erate, statistically nonsignificant reductions in re-
gional DV0 values were abolished except in the parietal
cortex, in which the parietal/thalamus ratio showed a
mean reduction of 25% (Fig. 2). This area coincided
with the region showing the largest reductions in
rCMRglu (Fig. 2, top row).
Regional three-compartment model
In Table III we present results obtained with the
three-compartment model configuration. Transport
rates (K1) were again observed to be significantly de-
creased in frontal and parietal cortices, thalamus,
pons, and cerebellum of AD subjects, compared with
age-matched controls, but not in the occipital cortex or
putamen. Focal reductions in K1 after normalization to
thalamic K1 values were apparent only in the parietal
cortex (mean change 20%).
The combined free and nonspecific volumes of distri-
bution (DV9) were similar across the brain regions an-
alyzed and between subject groups (ANOVA P . 0.05,
data not shown). With the more complex configuration,
the individual values of k3 and k4 suffered from high
statistical uncertainty (% coefficients of variation rang-
ing from 30–80%) (% coefficient of variation, %COV 5
(standard deviation 4 mean) 3 100). Therefore, the
binding potential (k3/k4) was used to provide a stable
index of binding density for this model configuration.
Mean regional k3/k4 ratios were generally lower in
AD patients than in elderly controls, with average re-
ductions ranging from 5% in occipital cortex to 30% in
parietal cortex, and intermediate values for the re-
maining regions. None of the regional values reached
statistically significant differences between AD and
age-matched controls.
Regional binding potential values were then normal-
ized to the thalamic values of each subject. Normaliza-
tion to a reference region would presumably eliminate
possible global differences in binding values that may
be present in AD, as well as intersubject variability
secondary to experimental factors. After normaliza-
tion, mean k3/k4 values were nearly identical between
AD patients, elderly controls, and young controls (Ta-
ble III). The only exception was an increase in normal-
ized binding potential at the level of the cerebellum
from the young control to the elderly control group (P ,
0.05), probably due to regional differences in age-re-
lated changes in muscarinic receptor concentrations in
these areas.
DISCUSSION
The present study was designed to examine the fea-
sibility of using [11C]NMPB for the quantification of
muscarinic receptor concentrations in aging and neu-
rodegenerative processes. We demonstrate age-related
reductions in muscarinic receptor binding measures,
but no evidence of regional changes in AD, which are
largely in agreement with postmortem data. A global
reduction in muscarinic binding in AD could not be
ruled out in this study, due to the variability inherent
to the utilization of a three-compartment kinetic model
to isolate blood flow from receptor changes.
We were primarily concerned with the unbiased es-
timation of two parameters, 1) transport of radiotracer
from plasma to brain compartment, K1, which is a
function of rCBF (tracer transport 5 flow 3 extrac-
tion), and 2) receptor binding. Prior results from our
laboratory using [11C]NMPB as a tracer indicated that
a pixel-by-pixel implementation of a two-compartment
tracer kinetic model was not completely able to isolate
changes in receptor density when tracer transport was
altered experimentally (Zubieta et al., 1998). This sit-
uation is likely to be encountered in the context of AD,
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in which reductions of both regional cerebral blood flow
and metabolism have been clearly documented in as-
sociative cortical regions (Frackowiak et al., 1981; Ben-
son et al., 1983; Foster et al., 1984; Friedland et al.,
1985; Haxby et al., 1990; Jagust et al., 1990; Johnson et
al., 1990). Using computer simulations based on aver-
age rate constants, pooled from 12 young healthy sub-
jects, we also showed that the use of the cerebellar
[11C]NMPB concentrations as an estimate of input
function were inaccurate, on the bases of significant
cerebellar specific binding and regional differences in
free tracer concentration (Zubieta et al., 1998). There-
fore, a three-compartment tracer kinetic model, which
was shown to accurately isolate tracer transport from
binding processes, was also applied in the analyses of
the present data.
Tracer transport was not found to be significantly
altered with advancing age. A trend towards a negative
correlation with age was noted in the frontal cortex
with the pixel-by-pixel model, which was not confirmed
in the three-compartment analysis. Global CBF does
not appear to be clearly altered with age (Itoh et al.,
1990; Martin et al., 1991), but mild reductions have
been shown in areas of the frontal, temporal, and pa-
rietal cortices (Pantano et al., 1984; Martin et al.,
1991). While K1 values are proportional to CBF, the
lesser extraction of [11C]NMPB than that of tracers
developed for the measurement of CBF, and the use of
Fig. 2. Pixel-by-pixel maps of regional cerebral metabolism ([18F]-
FDG), transport rates (K1), and receptor distribution volume (DV) in
a patient with probable AD. Marked reductions in glucose metabolism
and K1 are observed in parietal cortices, reflecting decreased function
and regional cerebral blood flow, respectively. While changes in the
receptor measure DV, obtained by a pixel-by-pixel implementation of
a two-compartment model, are not so pronounced, a change in this
region is still apparent. Receptor binding measures unbiased by the
effects of tracer delivery necessitated description by a more complex
three-compartment tracer kinetic model.
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relatively large regions of interest in the present study,
would not allow for the detection of small regional
differences in plasma to brain transport rates.
Muscarinic receptor binding parameters estimated
either with a two- or a three-compartment model (DV0
and k3/k4, respectively) showed significant reductions
with age in neocortical regions (frontal and occipital
cortices) and in thalamus, but not in putamen or cere-
bellum. These results are in general agreement with
those reported by Dewey et al. (1990) and Suhara et al.
(1993), although the degree of reduction we observe is
not as pronounced as that reported by these groups.
They observed similar or larger reductions in cortical
regions, and much larger age-related declines in the
striatum (caudate–putamen); thalamic changes were
reported only by Dewey et al. (1990). Differences be-
tween the present report and those studies may be
accounted for by the different methods used for quan-
tification of receptor densities and the radioligands
utilized. In the case of [N-11C-methyl]-benztropine
(Dewey et al., 1990), this agent appears to display a
slow ligand-receptor dissociation rate, which produces
uncertainties in the estimation of specifically bound
tracer volume of distribution that may impact on the
precision of the measurements. In the report by Suhara
et al. (1993) [11C]NMPB ligand-receptor binding was
calculated from a graphical method (Wong et al., 1986),
60 min of dynamic scanning, and utilizing the cerebel-
lum as input function. This differs from the present
report, in which a nongraphical kinetic analysis, actual
arterial blood sampling with correction for the presence
of metabolites, and a longer scanning period were uti-
lized. Given the kinetics of [11C]NMPB, which in areas
of high levels of specific binding (i.e., basal ganglia)
reaches equilibrium only at late times of the scanning
interval (Koeppe et al., 1992), shorter observation pe-
riods may lead to underestimations of ligand binding in
high receptor density regions. The measurements then
become susceptible to even small changes in delivery in
these areas (flow limited condition), with possible over-
estimations in age-related reductions in receptor bind-
ing. An additional factor that may have contributed to
the larger changes in muscarinic receptor binding with
are observed by Suhara et al. (1993), is that the cere-
bellum was utilized as a reference region for the calcu-
lation of binding potentials. This assumes that cerebel-
lar muscarinic binding is negligible, that the total
activity in the cerebellum reflects the input of radio-
tracer to the specifically bound compartment, and is
that not altered with advancing age. This may not be
the case, in view of the results reported by Lee et al.
(1996), in which higher cerebellar binding was ob-
served to increase with advancing age. In the present
report, we also observe a significant increase in mus-
carinic receptor binding with age in this region. The
use of this region as a reference would artifactually
enhance any reductions that may be present in other
areas.
The age-related reductions in muscarinic receptor
densities showed contrast with prior reports in living
human subjects using PET, both in the degree of
change and in number of regions showing statistically
significant differences between younger and older co-
horts. Conversely, they are similar to results obtained
with in vitro techniques using human postmortem ma-
terial (Perry, 1980) or animal models (Biegon et al.,
1988; Araujo et al., 1990). Alterations in muscarinic
receptor densities with advancing age may be at least
partially responsible for the increased sensitivity to
anticholinergic agents observed in older subjects (Mol-
chan et al., 1992).
TABLE III. [11C]NMPB kinetic parameter estimates, three-compartment model fits.
Alzheimer disease, age-matched controls, and young controls
Regions
K1 k3/k4
AD ECtr YCtr AD ECtr YCtr
Frontal cortex 0.27 (0.04)* 0.39 (0.04) 0.35 (0.07) 31 (19) 44 (21) 53 (18)
Parietal cortex 0.19 (0.03)* 0.34 (0.04) 0.33 (0.05) 33 (12) 47 (27) 50 (15)
Occipital cortex 0.35 (0.06) 0.40 (0.02) 0.37 (0.04) 47 (15) 57 (14) 49 (21)
Putamen 0.36 (0.03) 0.45 (0.05) 0.38 (0.07) 58 (28) 71 (48) 82 (27)
Thalamus 0.34 (0.09)* 0.48 (0.04) 0.41 (0.09) 20 (4) 26 (11) 31 (9)
Pons 0.33 (0.03)* 0.44 (0.08) 0.37 (0.09) 16 (5) 18 (9) 23 (8)
Cerebellum 0.34 (0.04)* 0.42 (0.05) 0.37 (0.05) 2 (1) 3 (1) 2 (1)
Region/Thalamus Ratios
Frontal cortex 0.9 (0.3) 0.8 (0.1) 1.7 (0.3) 1.6 (0.8) 1.7 (0.3) 1.7 (0.2)
Parietal cortex 0.6 (0.1)* 0.7 (0.1) 1.6 (0.2) 1.6 (0.4) 1.8 (0.4) 1.6 (0.2)
Occipital cortex 1.1 (0.6) 0.8 (0.1) 0.9 (0.2) 2.3 (0.5) 1.9 (0.4) 1.9 (0.5)
Putamen 1.2 (0.5) 0.9 (0.1) 1.9 (0.3) 2.7 (1.1) 2.5 (0.6) 2.7 (0.6)
Pons 1.1 (0.5) 0.9 (0.1) 0.9 (0.1) 0.8 (0.2) 0.7 (0.1) 0.8 (0.2)
Cerebellum 1.1 (0.5) 0.9 (0.1) 1.9 (0.3) 0.1 (0.05) 0.1 (0.04) 0.07 (0.03)*
Transport rate constants (K1) and binding potential (k3/k4) of [
11C]NMPB in patients diagnosed with Alzheimer disease
(AD), age-matched elderly controls (ECtr), and a young reference group (YCtr), calculated from a three-compartment
tracer kinetic model (standard deviation of the mean in parentheses). Statistical comparisons were performed between
AD and ECtr, and between ECtr and YCtr groups.
*Significantly different from elderly control group, ANOVA with post-hoc Dunnett t-tests, P , 0.05.
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In contrast to the results observed in normal aging,
patients diagnosed with AD demonstrate significant
reductions in tracer transport in most of the brain
regions studied. Largest reductions were noted in the
parietal cortex, followed in severity by frontal cortex,
thalamus, and pons, while occipital cortex, putamen,
and cerebellum differences did not reach statistical
significance. The parietal cortex was known to be most
affected metabolically because of the inclusion criteria
in the study (biparietal hypometabolism), and it was
expected that this area would display the more severe
reductions in regional CBF as well, impacting directly
on tracer transport rates.
In the context of limitations in tracer delivery, it was
of interest to compare the performance of a simpler
tracer kinetic approach (pixel-by-pixel implementation
of a two-compartment model, which yields parametric
images of K1 and DV0), with a more complex, hence
potentially less precise, but less biased regional three-
compartment tracer kinetic model. In the pixel-by-pixel
approach, significant reductions in the binding-related
parameter DV0 were identified in the parietal cortex of
patients diagnosed with AD compared with age-
matched controls. This finding was still apparent after
normalization to thalamic DV0 values. The thalamus
was selected as a reference area on the bases of prior
reports documenting the relative preservation of its
metabolic, regional CBF, and presumably neural func-
tion in AD (Frackowiak et al., 1981; Benson et al., 1983;
Foster et al., 1984; Friedland et al., 1985; Kantzman,
1986). Normalization to thalamic ligand binding values
served two purposes. It would differentiate individual
reductions secondary to aging from those due to the
illness, since the thalamus was one of the areas in
which age had a clear effect on muscarinic receptor
densities, but was less likely to be affected in AD. It
also helped reduce uncertainties that may be associ-
ated to interexperimental variability. This is of specific
interest in the interpretation of data derived from the
three-compartment tracer kinetic model, in which the
variance was increased by a larger number of un-
knowns (calculation of four rate constants, instead of
the two parameters estimated in the simpler model).
However, the use of a reference region assumes that no
changes in this area are present in the disease process
to be studied. While this may be the case in AD, normal
aging was associated with reductions in muscarinic
binding in the thalamus. This may introduce errors in
the comparison of regional binding between young and
older populations. This was observed in our data as
increases in the normalized cerebellar values in older
controls compared to young controls. Since the cerebel-
lum did not show changes with advancing age, normal-
ization to thalamus was likely to have introduced arti-
factual errors in this situation.
Using a three-compartment model configuration,
mean regional values of binding potential (k3/k4) were
generally lower in AD patients than in age-matched
controls, although those differences did not reach sta-
tistical significance for any of the regions analyzed.
This may reflect moderate global reductions in total
muscarinic receptor densities in AD, statistically unde-
tected because of the small sample and larger variance
of this model. After normalization to the individual
thalamic values the variability in the data was re-
duced, these changes were no longer apparent, and the
mean of the k3/k4 ratios were nearly identical between
patients diagnosed with AD, age-matched elderly con-
trols, and a young control reference group. In the
present example, the percent coefficient of variation in
the parietal cortex of AD patients was reduced from
37% to 23% after normalization. The largest variability
was observed in the frontal cortex of AD patients (62%
COV in the original data and 77% COV after normal-
ization) compared to that of age-matched controls (48%
before and 17% after normalization). The source of
variance in this region is unclear, although it may
reflect individual differences in disease process or the
existence of subtypes within the AD group (i.e., more
pronounced degeneration of frontal cholinergic projec-
tions). Any specific conclusions regarding possible sub-
types of clinically diagnosed AD, or relationships be-
tween muscarinic receptor densities and cognitive
function, are beyond the scope of the present study but
may be an area of interest for future research.
The data presented do not support the presence of
regional reductions in total muscarinic receptor densi-
ties in AD. It is possible, however, that mild to moder-
ate global changes in receptor availability may exist, as
suggested by the decreased mean binding potential in
all the brain regions considered. The small sample size
included in the data does not allow for more precise
conclusions: given the variance of the unnormalized
data, approximately 50% reduction in binding poten-
tial values would be required to find a significant dif-
ference between groups with that sample size at 80%
power and a one-tailed unpaired t-test. In addition,
more pronounced gray matter atrophy in AD could also
be responsible for some of the global reductions in the
muscarinic receptor measurements obtained with PET.
Our results are in clear contrast with those reported
by other groups (Holman et al., 1985; Weinberger et al.,
1991, 1992; Ichimiya et al., 1995). In the two former
series, the distribution of [123I]QNB was found to be
decreased in cortical association areas of patients with
AD. In the initial report by Holman et al., the reduction
in regional QNB uptake was of lesser degree than that
of the CBF tracer [123I]N-isopropyl p-iodoamphet-
amine. In subsequent descriptions (Weinberger et al.,
1991, 1992), it was noted that the uptake of labeled
QNB identified more abnormal regions, and was more
severely reduced than the metabolic patterns obtained
with [18F]FDG. This led to the proposal that the distri-
bution of the iodinated muscarinic antagonist was a
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more accurate measure of the degree of disease pro-
gression that metabolic imaging. In a later report
(Ichimiya et al., 1995), reductions in parietal cortex
tracer deposition were observed with [11C]NMPB using
a graphical analysis with cerebellum as input function.
The differences encountered between the present re-
port and prior studies are likely to be secondary to
differences in radiotracer kinetics and methods of
quantification employed. In this regard, estimates of
the NMPB dissociation rate from receptors (k4 values
0.06–0.10 min-1) (Zubieta et al., 1998) are higher than
for previously used tracers. This property allows more
accurate determination of ligand-receptor dissociation
rates during the limited time in which scanning can be
performed with 11C-labeled tracers. Additionally, re-
ceptor binding estimates that utilize a reference region
as input function (e.g., cerebellar activity; Ichimiya et
al., 1995) may suffer from significant biases. In the case
of the cerebellum, not all the tracer activity present in
this region represents free tracer (approximately half
is bound); free tracer concentration is also regionally
variable, so that its values could not be extrapolated
between regions (Zubieta et al., 1998). The distribution
volume of free and nonspecific tracer is approximately
[(K1/k2) 1 k3], and therefore it can be uniform without
the actual free concentration being the same. In this
manner, free tracer concentrations in cortical areas
and in the basal ganglia, rich in muscarinic receptors,
will be less than in an area with low muscarinic bind-
ing, such as the cerebellum.
Similar to the data presented, autopsy and biopsy
studies, in which the total number of muscarinic recep-
tors was quantified in vitro, uniformly describe a pres-
ervation of receptor densities in AD (Davies and Verth,
1978; Perry et al., 1978; Sakurada et al., 1990; Schro-
der et al., 1991; DeKosky et al., 1992). Since the non-
selective markers NMPB or QNB label all muscarinic
receptor subtypes, it is possible that alterations in the
densities of one of the subtypes would not be detected
by these radioligands. Currently, up to three subtypes
have been described using functional and pharmaco-
logical characterizations (Doods et al., 1987; Hulme et
al., 1990; Zubieta and Frey, 1993), and five have been
defined by molecular biologic techniques (Buckley et
al., 1988; Dorje et al., 1991; Levey et al., 1991). Addi-
tionally, it has been suggested that both presynaptic
degeneration and upregulatory processes may coexist
in AD (Harrison et al., 1991; Aubert et al., 1992), fur-
ther complicating the interpretation of data.
The work presented here points towards some possi-
ble future research directions. Primarily, that it is nec-
essary to develop radiotracers with more favorable ki-
netic properties and subtype selectivity for the study of
muscarinic receptors in neurogenerative processes. Se-
lective reductions in the M2 subtype have been re-
ported in vitro in cortical regions in some postmortem
studies of AD (Mash et al., 1985; Araujo et al., 1988;
Quirion et al., 1989; Rinne et al., 1989; Aubert et al.,
1992). In vivo human imaging with SPECT and (-)-5-
[123I]iodobenzovesamicol, a presynaptic marker of ve-
sicular uptake sites, has shown reductions in patients
with AD in cortical and, to a lesser extent, in basal
ganglia regions, and suggested regionally specific pat-
terns of neuronal degeneration in early- and late-onset
illness (Kuhl et al., 1996). Further development in this
area is of special importance with the appearance of
pharmacological treatments for AD. Monitoring of
treatment responses and investigation of the actions of
novel drugs could be accomplished noninvasively with
these techniques. Further subtyping of AD at early
stages of the disease, when treatment intervention
could be successful when better targeted to specific
patterns of degeneration, would also be of interest in
this field.
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